Skip to main content

ORIGINAL RESEARCH article

Front. Pharmacol.
Sec. Cardiovascular and Smooth Muscle Pharmacology
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1437760
This article is part of the Research Topic Exploring Small Molecule Inhibitors in Cardiovascular and Cerebrovascular Diseases View all 5 articles

Bibliometric and visual analysis of SGLT2 inhibitors in cardiovascular diseases

Provisionally accepted
Runfang Pan Runfang Pan 1Yuqing He Yuqing He 1Melisandre Wan Melisandre Wan 1Yunyi Zhang Yunyi Zhang 1Wenyuan Su Wenyuan Su 2Jiaming Feng Jiaming Feng 1Chengyao Jia Chengyao Jia 3Shaoling Li Shaoling Li 4Baonian Liu Baonian Liu 1*
  • 1 Shanghai University of Traditional Chinese Medicine, Shanghai, China
  • 2 Shanghai University of Sport, Shanghai, Shanghai Municipality, China
  • 3 National Sun Yat-sen University, Kaohsiung, Kaohsiung County, Taiwan
  • 4 Tongji University, Shanghai, Shanghai Municipality, China

The final, formatted version of the article will be published soon.

    Background: Cardiovascular diseases (CVD) pose a significant threat to human health due to their high mortality and morbidity rates. Despite advances in treatments, the prevalence and impact of cardiovascular disease continue to increase. Sodium-glucose transporter 2 inhibitors (SGLT2i), initially approved for the treatment of type 2 diabetes, have important research value and promising applications in reducing CVD risk, especially in heart failure (HF) and atherosclerosis patients with cardiovascular disease (ASCVD). This study aims to comprehensively review the latest progress, research trends, cutting-edge hot spots, and future development directions of SGLT2i in the field of CVD through bibliometric analysis.Methods: Articles related to MSCs in cardiovascular diseases were sourced from the Web of Science. The bibliometric analysis was conducted using CiteSpace and VOSviewer, and a knowledge map was created based on the data obtained from the retrieved articles.In this article, we screened 3,476 relevant studies, including 2,293 articles and 1,183 reviews. The analysis found that the number of papers related to the application of SGLT2i in CVD has generally increased, peaking in 2022. The United States and China contributed the largest number of papers, with the United States accounting for 36.97% of the total and also ranking first in terms of the number of citations. However, China's high-quality papers are slightly lacking and need further improvement.Keyword analysis showed that empagliflozin, dapagliflozin, diabetes, and heart failure were the most common terms, reflecting the main research interests in currently published papers in this field.: Bibliometric analysis showed a robust and growing interest in the application of SGLT2i for treating CVD. By summarizing the latest progress of SGLT2i in the field of CVD, exploring research hotspots, and looking forward to future research development trends, this article provides valuable insights for thinking about research prospects.

    Keywords: Sodium-glucose transporter 2 inhibitor, cardiovascular disease, Bibliometric Study, Citespace, VOSviewer

    Received: 24 May 2024; Accepted: 21 Oct 2024.

    Copyright: © 2024 Pan, He, Wan, Zhang, Su, Feng, Jia, Li and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Baonian Liu, Shanghai University of Traditional Chinese Medicine, Shanghai, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.